Cite
HARVARD Citation
Backes, F. et al. (n.d.). 2022-RA-708-ESGO Real-world assessment of patients with ovarian cancer who received niraparib as second-line maintenance therapy in the United States: did first-line maintenance approval change the patient profile for second-line maintenance therapy?. International journal of gynecological cancer. pp. A258-A259. [Online].